trending Market Intelligence /marketintelligence/en/news-insights/trending/TfuSD8XJsP7LDvqvPWN4JQ2 content esgSubNav
In This List

Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Lexicon Pharmaceuticals Inc.'s investigational, oral diabetes drug sotagliflozin met its primary endpoint in a phase 3 clinical trial.

The company was studying the treatment in type 1 diabetes patients who were on insulin therapy. The study met its primary endpoint after demonstrating superiority over placebo and a well-tolerated safety profile during a 24-week treatment period.

Results from the study will be submitted for publication in a peer-reviewed journal.

The drug is also being studied in adults with type 2 diabetes.